Clinical Trials

Our Fertility Research Program conducts clinical trials as part of a commitment to developing innovative technologies and improve fertility success rates. Patients who qualify for these trials may take advantage of discounted treatments and medications.

To find out if we are currently enrolling in a program, please email us at info@fertility-miami.com

Past Clinical Trials

FERRING: A Phase 4, randomized, assessor-blind trial comparing MENOPUR® and Recombinant FSH in a GnRH Antagonist cycle with single-blastocyst transfer in a high responder subject population. Initiated 8/1/2015. Completed.

ROCHE Diagnostic Operations: A multi-center, prospective, non-interventional study into the value of AMH for the assessment of ovarian reserve in women presenting to fertility centers for evaluation, in conjunction with other clinical and laboratory findings. Clinical performance study. Initiated 2/1/2015. Completed.

MERCK: A Phase 3, randomized, double-blind, active-controlled, non-inferiority trial to investigate the efficacy and safety of a single injection of SCH 900962 (corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (recFSH) as a reference in women aged 35 to 42 years. Initiated 8/1/2010. Completed

EMD SERONO Inc.: A Phase II, multicenter, randomized, assessor-blinded, active-comparator, dose-finding study to evaluate AS900672-enriched versus Follitropin Alpha (Gonal-f®) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology (ART). Initiated 5/7/2007. Completed.

ORGANON USA, Inc.: A phase IV, randomized, open-label clinical trial to identify predictive factors for controlled stimulation using fixed daily dose of 200 IU of recombinant FSH in a GnRH antagonist regimen with or without oral contraceptive scheduling. Initiated 10/11/2006. Completed.

ORGANON USA, Inc.: Does 200 IU give as consistent a response as 225 IU in normal responding IVF/ICSI patients using the Follistim PenT to deliver Follistim AQ®. Initiated July 2006. Completed.

SERONO Laboratories, Inc.: A phase III, prospective, randomized, assessor blind, multicenter, comparative trial of a new formulation of r-FSH versus Fertinex and Gonal-F in oligoanovulatory infertile women undergoing ovulation induction. Initiated 4/26/2001. Completed.

FERRING Pharmaceutical, Inc.: “A randomized, double-blind double-dummy trial comparing MENOPUR solution for injection in a pre-filled pen and MENOPUR powder and solvent for solution for injection (menotropins for injection) in a GnRH agonist cycle in women aged 18-42 years undergoing an assisted reproductive technology program”.

SERONO Laboratories, Inc.: A phase III, multinational, randomized, assessor-blind study to compare the safety and efficacy of a new formulation of recombinant human FSH (s-FSH) versus Fertinex versus Gonal-F in stimulating multiple follicular development prior to ART in patients pretreated with GnRH agonist. Initiated 8/1/2000. Completed.

Siemens Healthcare Diagnostics: “ADVIA Centaur AMH Ovarian Reserve Specimen Collection Protocol”.